GENEART Awarded European Patent for Tested HIV Vaccines
Complete the form below to unlock access to ALL audio articles.
The GENEART AG announces the award of the patent EP 1240333 titled "Das Genom des HIV-1 Intersubtyps (C/B') und seine Anwendungen" ("The Genome of HIV-1 Intersubtype (C/B') and Use Thereof") by the European Patent Office.
The above-mentioned patent protects the use of certain custom-designed HIV gene sequences for the development of therapeutics or vaccines in the following countries: Austria, Belgium, France, Germany, Great Britain, Italy, Luxembourg, the Netherlands, Spain and Switzerland. The US American patent of the patent family was already assigned in February.
The patent describes gene sequences, which have already been successfully tested as HIV vaccine candidates in a phase I clinical trial. The results of the clinical trial have been published in "The Journal of Experimental Medicine" (Vol. 205, 63-77).
Currently, the gene sequences are tested in a phase I/II trial by the EuroVacc Foundation. As a licensor, GENEART provides the patented gene sequences (structural design) for these trials.
